Cargando…

Hypercoagulable state in COVID-19 with diabetes mellitus and obesity: Is therapeutic-dose or higher-dose anticoagulant thromboprophylaxis necessary?

Detalles Bibliográficos
Autores principales:	Wijaya, Indra, Andhika, Rizky, Huang, Ian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Diabetes India. Published by Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362820/ https://www.ncbi.nlm.nih.gov/pubmed/32683322 http://dx.doi.org/10.1016/j.dsx.2020.07.015

Ejemplares similares

The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review
por: Wijaya, Indra, et al.
Publicado: (2020)

Challenge in diagnosis of COVID-19 in hemodialysis patient: a case report and brief review of the literature
por: Andhika, Rizky, et al.
Publicado: (2021)

The effects of aspirin on the outcome of COVID-19: A systematic review and meta-analysis
por: Wijaya, Indra, et al.
Publicado: (2021)

Identification of hypercoagulability with thrombelastography in patients with hip fracture receiving thromboprophylaxis
por: You, Daniel, et al.
Publicado: (2021)

Hypercoagulability in Cushing’s syndrome: incidence, pathogenesis and need for thromboprophylaxis protocols
por: Feelders, Richard A., et al.
Publicado: (2022)

Weight-adjusted dosing of tinzaparin for thromboprophylaxis in obese medical patients
por: Pfrepper, Christian, et al.
Publicado: (2023)

Therapeutic-dose anticoagulation or thromboprophylaxis with low-molecular-weight heparin for moderate Covid-19: meta-analysis of randomized controlled trials
por: Ena, Javier, et al.
Publicado: (2022)

Non‐severe COVID‐19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis
por: Kelliher, Sarah, et al.
Publicado: (2022)

EFFECT OF ANTICOAGULATION AND ANTIPLATELET AGENTS ON HYPERCOAGULABILITY STATES IN PATIENTS WITH COVID-19
por: UR, JEANNIE, et al.
Publicado: (2021)

The Role of Anticoagulation in COVID-19-Induced Hypercoagulability
por: Rico-Mesa, Juan Simon, et al.
Publicado: (2020)

Warfarin Dosing and Time Required to Reach Therapeutic International Normalized Ratio in Patients with Hypercoagulable Conditions
por: Kahlon, Pushpinderdeep, et al.
Publicado: (2016)

Anticoagulation Protocols in Hypercoagulable Microvascular Head and Neck Reconstruction
por: Egan, Katie G., et al.
Publicado: (2019)

The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis
por: Wijaya, Indra, et al.
Publicado: (2021)

Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants
por: Nakashima, Megan O., et al.
Publicado: (2014)

Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
por: Rappaport, Stephen H., et al.
Publicado: (2020)

Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients
por: Jonmarker, Sandra, et al.
Publicado: (2020)

Thromboprophylaxis in COVID‐19: Weight and severity adjusted intensified dosing
por: Engelen, Matthias M., et al.
Publicado: (2022)

Thromboprophylaxis and anticoagulation for inpatients with COVID-19 in 2022 and beyond
por: Dalager-Pedersen, Michael
Publicado: (2022)

Metabolic consequences of obesity on the hypercoagulable state of polycystic ovary syndrome
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

Thromboprophylaxis in COVID-19: Early initiation might be as important as optimal dosing
por: Kollias, Anastasios, et al.
Publicado: (2021)

Role of Direct Oral Anticoagulation Agents as Thromboprophylaxis in Antiphospholipid Syndrome
por: Arora, Shreya, et al.
Publicado: (2021)

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis
por: Cuker, Adam, et al.
Publicado: (2022)

Rare Presentation of Deep Vein Thrombosis and Submassive Pulmonary Emboli Due to Hypercoagulable State With Supratherapeutic Anticoagulation
por: Rivera-Morales, Mark D, et al.
Publicado: (2021)

A Case Series of Thromboelastography-Guided Anticoagulation in COVID-19 Patients with Inherited and Acquired Hypercoagulable States
por: Thomas, Anthony V., et al.
Publicado: (2021)

Hypercoagulability and Anticoagulation in Patients With COVID-19 Requiring Renal Replacement Therapy
por: Roberts, Lara N., et al.
Publicado: (2020)

COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy
por: Daughety, Molly M., et al.
Publicado: (2020)

Immune Responses and Hypercoagulation in ERT for Pompe Disease Are Mutation and rhGAA Dose Dependent
por: Nayak, Sushrusha, et al.
Publicado: (2014)

Correlation Between Higher Cumulative Dose of Cisplatin for Concurrent Chemoradiation and Acute Kidney Disease Incidence Among Nasopharyngeal Carcinoma Patients: A Comparative Study
por: Rachman, Andhika, et al.
Publicado: (2021)

Thromboprophylaxis with standard-dose vs. flexible-dose heparin for hospitalized COVID-19 patients: a target trial emulation
por: Martínez-Alés, Gonzalo, et al.
Publicado: (2022)

SUN-237 Higher Doses of Testosterone Gel Required in Hypogonadal Men with Obesity to Achieve Therapeutic Replacement - Advice on Dose Titration
por: Mumdzic, Enis, et al.
Publicado: (2019)

Prevalence of hypercoagulable states in stented thrombotic iliac vein compression syndrome with comparison of re-intervention and anticoagulation regimens
por: Cramer, Peyton, et al.
Publicado: (2021)

The hypercoagulable states in anaesthesia and critical care
por: Bande, Bala D, et al.
Publicado: (2014)

Serum hypercoagulability states in Coats’ disease
por: Ghassemi, Fariba, et al.
Publicado: (2017)

Intermediate dose thromboprophylaxis in SARS-CoV-2 related venous thrombo embolism
por: Haider, Zahra, et al.
Publicado: (2021)

How to assess hypercoagulability in heparin-induced thrombocytopenia? Biomarkers of potential value to support therapeutic intensity of non-heparin anticoagulation
por: Barocas, Antoine, et al.
Publicado: (2023)

High-dose versus low-dose venous thromboprophylaxis in hospitalized patients with COVID-19: a systematic review and meta-analysis
por: Valeriani, Emanuele, et al.
Publicado: (2022)

New Oral Anticoagulants for Thromboprophylaxis after Elective Total Hip and Knee Arthroplasty
por: Friedman, Richard J.
Publicado: (2010)

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19
por: Cuker, Adam, et al.
Publicado: (2021)

Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites?
por: Lee, Jessica W., et al.
Publicado: (2019)

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients
por: Cuker, Adam, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q87g4ob8vfqpjjvc23u1v785a4